Alle Storys
Folgen
Keine Story von NANOSONICS LTD. mehr verpassen.

NANOSONICS LTD.

Ultrasound Transducer Disinfection in many Cases insufficient

Hamburg (euro adhoc) -

New ‘Trophon EPR’ Device offers unique Solution
  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
innovations
Current methods of ultrasound transducer
disinfection are in many cases not sufficient for clinical practice. 
This is the latest alarming result issued by the Center for Disease 
Control and Prevention (CDC), the leading US public health agency, in
its recently published Guideline for Disinfection and Sterilization 
in Healthcare Facilities. (1) The guideline is the CDC´s response to 
the rapidly evolving epidemiology of hospital-acquired infections 
such as Clostridium difficile (2) or MRSA (3).
In light of this global threat, and with regard to the millions of 
ultrasound examinations conducted each day, Nanosonics´ newest 
product innovation represents a long-needed milestone in the 
development of medical devices: due to its unique technology, the 
Trophon EPR completely satisfies all requirements of the new CDC 
guideline.
Whereas current methods for high-level disinfection of contaminated 
transvaginal and transrectal transducers (e.g. aldehydes, alcohol or 
chlorine) show considerable drawbacks, the Trophon EPR has been 
custom designed to disinfect intracavity and surface ultrasound 
transducers, while combining speed, safety and convenience. It 
delivers high-level disinfection plus (HLD+), including sporicidal 
efficacy, in only six minutes operating time. The fully automated 
device can be used directly at the point of care, is easy to operate 
and is environmentally friendly, leaving water and oxygen as the only
by-products.
The Trophon EPR was officially presented at this year´s MEDICA, which
took place in Düsseldorf, Germany, from 19 to 22 November, 2008. "We 
recognised the danger presented by the inadequate disinfection of 
ultrasound transducers, and know that the Trophon EPR will be 
indispensable for the urgently needed hygiene necessary in the 
medical sector, to guarantee the safety of each and every patient", 
explained David Radford, Director and CEO of Nanosonics Limited, 
Australia, prior to the impending market launch.
The product technology has been validated by major OEM´s (e.g. 
Philips) and dealer commitments have already been approved in several
European countries. The European launch of the Trophon EPR is 
scheduled to start in the first half of 2009. For more information 
about Nanosonics, the Trophon EPR and its platform technology 
(NanoNebulant™) please visit the Company´s websites at 
www.nanosonics.eu and www.trophon.com.au.
About Nanosonics
The company is of Australian origin, located in Alexandria, Sydney, 
with European headquarters in Hamburg, Germany. Nanosonics has been 
listed on the Australian Securities Exchange (NAN) and Frankfurt 
Stock Exchange (OQM) since 2007.
The company owns intellectual property relating to unique 
disinfection and sterilisation technologies, which can be suited to a
variety of markets including the healthcare industry, food 
processing, room and space decontamination, and manufacturing.
Nanosonics is currently focused on developing infection control 
solutions for the global healthcare market. Initial applications are 
designed for the reprocessing of reusable medical instruments. The 
Trophon EPR is specifically designed to disinfect intracavity and 
surface ultrasound probes. Based on the NanoNebulant™ technology it 
surpasses the limitations of current methods by killing the most 
resilient micro-organisms, in a fast, safe and convenient way.
(1) Rutala WA, Weber DJ, Healthcare Infection Control Practices 
Advisory Committee. Guideline for Disinfection and Sterilization in 
Healthcare Facilities, 2008. 
http://www.cdc.gov/ncidod/dhqp/sterile.html.
(2) Association for Professionals in Infection Control and 
Epidemiology (APIC). Press release, Orlando, 11 November 2008: 
Intestinal infection afflicts 13 of 1,000 hospital patients; 
infection rates 6.5-20 times greater than previous estimates, new 
study says.
(3) Orsi GB. MRSA: an old and new enemy. Healthcare Infection 2008; 
13:73-75.
World Headquarters
Nanosonics Ltd.
Unit 24, 566 Gardeners Road
Alexandria NSW 2015
Australia
http://www.nanosonics.com.au
European Headquarters
Nanosonics Europe GmbH
Falkenried 88, House E
20251 Hamburg
Germany
http://www.nanosonics.eu
end of announcement                               euro adhoc

Further inquiry note:

Nikola Heimann
Telefon: +49(0)40-35543624
E-Mail: nikola.heimann@plus-pool.de

Branche: Biotechnology
ISIN: AU000000NAN9
WKN: A0MQVE
Börsen: Börse Berlin / Open Market
Börse Frankfurt / Open Market